Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY). On June 2, 2025, Blueprint Medicines announced the execution of a definitive agreement with Sanofi for the acquisition of all outstanding shares of Blueprint Medicines for $129.00 per share in cash. Whereas shareholders also ...